Janux Therapeutics, Inc. (JANX) company profile
Close on Nov 17, 2026Market cap $654.78MP/E –Yield –
About Janux Therapeutics
Pharmaceutical Preparations, SIC 2834
Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and autoimmune conditions. The company utilizes its proprietary TRACTr, TRACIr, and ARM technology platforms to create engineered bispecific molecules and T cell engagers. Its main clinical-stage candidates include JANX007, an investigational TRACTr therapy designed to treat metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeting TRACTr being evaluated across various solid tumor indications. In addition, the firm is advancing JANX011 for autoimmune diseases. While its clinical candidates are designed to treat patients, the company also engages with large biopharmaceutical collaborators such as Merck Sharp & Dohme and Bristol Myers Squibb.
The company's pipeline assets undergo clinical and nonclinical evaluation across multiple study cohorts and indications, though the text does not disclose operational metrics, facility counts, geographic footprints, or the location of its corporate headquarters.
Summary of the business section of Janux Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Janux Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10955 Vista Sorrento Parkway, Suite 200 92130
- Phone
- (858) 751-4493
- Website
- januxrx.com
- Employees
- 109, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- JANX
- Exchange
- Nasdaq
- IPO date
- Jun 11, 2021
- Shares outstanding
- 61M, Aug 4, 2026
- Public float
- $1.10B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1817713
- CUSIP
- 47103J105
- ISIN
- US47103J1051
- FIGI
- BBG00ZHSKH11
- Share class FIGI
- BBG00ZHSKH39
- EIN
- 82-2289112
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Alan Campbell | President and CEO, Director | 264,742 |
| Janeen Noel Doyle | Chief Corp. & Bus. Dev. Ofcr | 75,941 |
| Maria Dobek | Vice President, Accounting | 32,270 |
| William Go | Chief Medical Officer | 44,000 |
| Andrew Hollman Meyer | Chief Business Officer | 83,095 |
| Charles M. Winter | Chief Technical Officer | 77,721 |
| Thomas DiRaimondo | Chief Scientific Officer | 155,825 |
| Zachariah McIver | Chief Medical Officer | 23,286 |
| Byron Robinson | Chief Strategy Officer | 28,000 |
| Vickie L. Capps | Director | 79,598 |
| Jake Simson | Director | 11,750 |
| Capital Healthcare Fund LP RA | Director | 6,250 |
| Ronald W. Barrett | Director | 11,750 |
| Eric Dobmeier | Director | 15,481 |
| RA Capital Nexus Fund II, L.P. | Director | 11,750 |
| Winston Kung | Director | 11,750 |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | 9,317,246 |
| Natasha Hernday | Director | 15,481 |
| Ra Capital Management, L.P. | Director | 2,500 |
| Alana B. McNulty | Director | 6,250 |
| Sheila Gujrathi | Director | 118,889 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.51M | -$17.75M | $4.61M | $105 | $135 |
| FY2024 | $8.97M | $55.19M | $5.05M | $407 | $102 |
| FY2023 | $4.19M | $1.05M | $1.67M | $81 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| David Campbell President and Chief Executive Officer | $680.00K | – | – | $12.46M | $367.20K | – | $13.51M | +50% |
| Thomas DiRaimondo Chief Scientific Officer | $478.00K | – | – | $3.69M | $175.90K | – | $4.35M | +27% |
| Janeen Doyle Chief Corporate and Business Development Officer | $309.96K | $75.00K | $995.28K | $3.12M | $114.07K | $50.00K | $4.67M | – |
| Zachariah McIver Former Chief Medical Officer | $475.00K | – | – | $4.00M | $165.30K | – | $4.64M | – |
| Byron Robinson Former Chief Strategy Officer | $362.73K | – | – | $4.31M | – | $394.08K | $5.06M | +33% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 11, 2021
- Offer price
- $17.00
- Securities offered
- 11,400,000
- Gross proceeds
- $193.80M
- Exchange
- Nasdaq
- First trading day
- Jun 11, 2021
- First-day close
- $25.15+47.9%
- Lock-up ends (est.)
- Dec 8, 2021
“Per Share Total Initial public offering price $ 17.00 $ 193,800,000 Underwriting discounts and commissions (1) $ 1.19 $ 13,566,000 Proceeds, before expenses, to us $ 15.81 $ 180,234,000 (1) See the section titled “Underwriting” for a description of the compensation payable to the underwriters.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 109 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 20, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 11, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 9, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?